This anti-CD73/PDL1-HLE biologic improved the control of tumor growth in the aggressive B16F10 melanoma model, or even induced complete tumor rejection in the EG7 model, as well as improved mice survival in both tumor models (Figures 5B, C and 6B, C). This evidence concerns the gene CD274 and melanoma.